Kyverna Therapeutics, Inc. (KYTX)
D
Pipeline Grade
Financial Position (from SEC Filings)
$32.2M
Cash & Equivalents
$41.6M
Quarterly Burn Rate
2 mo
Est. Cash Runway
$516M
Market Cap
Estimated from most recent SEC quarterly filing. View SEC filings
Drug Pipeline (0 Assets)
No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.
Upcoming Catalysts
| Date | Event | Drug |
|---|---|---|
| 2027-04-01 | Phase2 Readout | — |
Active Clinical Trials (4)
| NCT # | Title | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT06193889 | KYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Patients With Generalized Myasthenia Gravis | PHASE3 | Recruiting | 66 |
| NCT06400303 | KYSA-5: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Systemic Sclerosis | PHASE2 | Active Not Recruiting | 3 |
| NCT06342960 | KYSA-3: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Refractory Lupus Ne... | PHASE2 | Active Not Recruiting | 2 |
| NCT06384976 | KYSA-7: A Study of Anti-CD19 CAR T-Cell Therapy, in Subjects With Refractory Primary and Secondary Progressive Multiple ... | PHASE2 | Active Not Recruiting | 120 |
Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.